New drug combo tested for scarred livers

NCT ID NCT06269484

Summary

This study tested whether a combination of two drugs (zibotentan and dapagliflozin) is safe for people with liver cirrhosis. Researchers compared the combination against each drug alone and against a placebo in 73 patients across multiple countries. The main goal was to monitor side effects, particularly fluid retention and weight gain.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Englewood, Colorado, 80113, United States

  • Research Site

    Charleston, South Carolina, 29425, United States

  • Research Site

    San Antonio, Texas, 78215, United States

  • Research Site

    Adelaide, 5000, Australia

  • Research Site

    Kogarah, 2217, Australia

  • Research Site

    Mitcham, 3132, Australia

  • Research Site

    Mechelen, 2800, Belgium

  • Research Site

    Liberec, 460 63, Czechia

  • Research Site

    Mladá Boleslav, 293 01, Czechia

  • Research Site

    Prague, 140 21, Czechia

  • Research Site

    Leipzig, 04103, Germany

  • Research Site

    Tübingen, 72076, Germany

  • Research Site

    Milan, 20122, Italy

  • Research Site

    Padua, 35128, Italy

  • Research Site

    Roma, 00168, Italy

  • Research Site

    Gifu, 500-8513, Japan

  • Research Site

    Kawasaki-shi, 215-0026, Japan

  • Research Site

    Kitakyusyu-shi, 806-8501, Japan

  • Research Site

    Nagaoka-shi, 940-2085, Japan

  • Research Site

    Niigata, 951-8520, Japan

  • Research Site

    Sapporo, 006-8555, Japan

  • Research Site

    Yokohama, 236-0004, Japan

  • Research Site

    Bydgoszcz, 85-794, Poland

  • Research Site

    Katowice, 40-081, Poland

  • Research Site

    Mysłowice, 41-400, Poland

  • Research Site

    Poznan, 61-848, Poland

  • Research Site

    Bratislava, 83104, Slovakia

  • Research Site

    Nitra, 950 01, Slovakia

  • Research Site

    Trnava, 91702, Slovakia

  • Research Site

    Aberdeen, AB25 2ZN, United Kingdom

  • Research Site

    Hull, HU3 2KZ, United Kingdom

  • Research Site

    Ipswich, IP4 5PD, United Kingdom

  • Research Site

    London, SE5 9RS, United Kingdom

  • Research Site

    Nottingham, NG7 2UH, United Kingdom

Conditions

Explore the condition pages connected to this study.